Ionis Pharmaceuticals Inc to Post FY2018 Earnings of ($0.48) Per Share, Leerink Swann Forecasts (IONS)

Ionis Pharmaceuticals Inc (NASDAQ:IONS) – Leerink Swann issued their FY2018 EPS estimates for Ionis Pharmaceuticals in a report released on Tuesday, November 27th. Leerink Swann analyst M. Foroohar forecasts that the company will post earnings of ($0.48) per share for the year. Leerink Swann currently has a “Market Perform” rating and a $50.00 target price on the stock. Leerink Swann also issued estimates for Ionis Pharmaceuticals’ Q4 2018 earnings at ($0.13) EPS, Q1 2019 earnings at $0.70 EPS, Q2 2019 earnings at ($0.11) EPS, Q3 2019 earnings at ($0.15) EPS, Q4 2019 earnings at ($0.19) EPS and FY2019 earnings at $0.25 EPS.

A number of other research firms have also weighed in on IONS. Stifel Nicolaus upped their price target on shares of Ionis Pharmaceuticals from $45.00 to $48.00 and gave the stock a “hold” rating in a research report on Tuesday, September 25th. Morgan Stanley set a $46.00 price target on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, November 7th. Piper Jaffray Companies set a $50.00 price target on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, November 6th. ValuEngine upgraded shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 9th. Finally, Zacks Investment Research lowered shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 9th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $53.50.

IONS opened at $57.43 on Friday. Ionis Pharmaceuticals has a 1-year low of $39.07 and a 1-year high of $58.54. The company has a quick ratio of 7.96, a current ratio of 7.99 and a debt-to-equity ratio of 0.74.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Tuesday, November 6th. The company reported ($0.03) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.10. The business had revenue of $145.40 million during the quarter, compared to analyst estimates of $146.77 million. Ionis Pharmaceuticals had a negative net margin of 7.52% and a negative return on equity of 1.58%. The company’s revenue was up 22.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.02) earnings per share.

Several large investors have recently modified their holdings of IONS. Principal Financial Group Inc. boosted its position in shares of Ionis Pharmaceuticals by 4.0% during the first quarter. Principal Financial Group Inc. now owns 38,277 shares of the company’s stock worth $1,687,000 after acquiring an additional 1,479 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Ionis Pharmaceuticals by 7.3% during the second quarter. Bank of Montreal Can now owns 18,950 shares of the company’s stock worth $789,000 after acquiring an additional 1,288 shares during the last quarter. Janney Montgomery Scott LLC boosted its position in shares of Ionis Pharmaceuticals by 5.0% during the second quarter. Janney Montgomery Scott LLC now owns 51,708 shares of the company’s stock worth $2,155,000 after acquiring an additional 2,461 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Ionis Pharmaceuticals by 23.5% during the second quarter. BNP Paribas Arbitrage SA now owns 17,137 shares of the company’s stock worth $714,000 after acquiring an additional 3,256 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its position in shares of Ionis Pharmaceuticals by 134.1% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 358,351 shares of the company’s stock worth $14,932,000 after acquiring an additional 205,250 shares during the last quarter. Hedge funds and other institutional investors own 85.87% of the company’s stock.

In related news, COO Brett P. Monia sold 34,000 shares of the company’s stock in a transaction on Friday, November 23rd. The shares were sold at an average price of $55.00, for a total transaction of $1,870,000.00. Following the completion of the transaction, the chief operating officer now owns 49,841 shares in the company, valued at $2,741,255. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP C Frank Bennett sold 12,500 shares of the company’s stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $49.54, for a total transaction of $619,250.00. Following the transaction, the senior vice president now owns 31,896 shares of the company’s stock, valued at approximately $1,580,127.84. The disclosure for this sale can be found here. Corporate insiders own 2.13% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Featured Story: Average Daily Trade Volume – What You Need to Know

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply